Regatul Unit - engleză - MHRA (Medicines & Healthcare Products Regulatory Agency)

glaxosmithkline uk ltd - amoxicillin sodium - powder for solution for injection - 500mg

Regatul Unit - engleză - MHRA (Medicines & Healthcare Products Regulatory Agency)

glaxosmithkline uk ltd - amoxicillin sodium - powder for solution for injection - 1gram

Filipine - engleză - FDA (Food And Drug Administration)

glaxosmithkline phils inc - amoxicillin , clavulanic acid - tablet - 500mg + 125mg

Filipine - engleză - FDA (Food And Drug Administration)

glaxosmithkline philippines, inc. - amoxicillin , clavulanic acid - powder for suspension - 400mg + 57mg / 5ml

Filipine - engleză - FDA (Food And Drug Administration)

glaxosmithkline philippines, inc. - co-amoxiclav (see reverse for formulation) - tablet - 1g

Noua Zeelandă - engleză - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - amoxicillin trihydrate 28.698 mg/ml equivalent to amoxycillin 25mg/ml;  ; potassium clavulanate 7.446 mg/ml equivalent to clavulanic acid 6.25mg/ml - powder for oral suspension - 125 mg/5ml - active: amoxicillin trihydrate 28.698 mg/ml equivalent to amoxycillin 25mg/ml   potassium clavulanate 7.446 mg/ml equivalent to clavulanic acid 6.25mg/ml excipient: aspartame colloidal silicon dioxide golden syrup flavour 52927 ap0551 hydrated silica hypromellose orange flavour phs-134215 orange flavour sd653970 raspberry flavour nn07943 succinic acid xanthan gum - augmentin should be used in accordance with local official antibiotic prescribing guidelines and local susceptibility data. augmentin is indicated for the short term treatment of common bacterial infections in adults and children such as: upper respiratory tract infections (including ent): e.g. tonsillitis, sinusitis, otitis media lower respiratory tract infections: e.g. acute exacerbations of chronic bronchitis, lobar and broncho pneumonia genito-urinary tract infections: e.g. cystitis, urethritis, pyelonephritis, female genital infections skin and soft tissue infections bone and joint infections: e.g. osteomyelitis other infections: e.g. septic abortion, puerperal sepsis, intra-abdominal sepsis, septicaemia, peritonitis, post-surgical infections susceptibility to augmentin will vary with geography and time. local susceptibility data should be consulted where available, and microbiological sampling and susceptibility testing performed where necessary. infections caused by amoxicillin susceptible organisms are amenable to augmentin treatment due to its amoxicillin content. mixed infections caused by amoxicillin susceptible organism in conjunction with augmentin susceptible beta-lactamase-producing organisms may therefore be treated by augmentin.

Noua Zeelandă - engleză - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - amoxicillin trihydrate 57.394 mg/ml equivalent to amoxycillin 50mg/ml;  ; potassium clavulanate 14.89 mg/ml equivalent to clavulanic acid 12.5mg/ml - powder for oral suspension - 250 mg/5ml - active: amoxicillin trihydrate 57.394 mg/ml equivalent to amoxycillin 50mg/ml   potassium clavulanate 14.89 mg/ml equivalent to clavulanic acid 12.5mg/ml excipient: aspartame colloidal silicon dioxide golden syrup flavour 52927 ap0551 hydrated silica hypromellose orange flavour phs-134215 orange flavour sd653970 raspberry flavour nn07943 succinic acid xanthan gum - augmentin should be used in accordance with local official antibiotic prescribing guidelines and local susceptibility data. augmentin is indicated for the short term treatment of common bacterial infections in adults and children such as: upper respiratory tract infections (including ent): e.g. tonsillitis, sinusitis, otitis media lower respiratory tract infections: e.g. acute exacerbations of chronic bronchitis, lobar and broncho pneumonia genito-urinary tract infections: e.g. cystitis, urethritis, pyelonephritis, female genital infections skin and soft tissue infections bone and joint infections: e.g. osteomyelitis other infections: e.g. septic abortion, puerperal sepsis, intra-abdominal sepsis, septicaemia, peritonitis, post-surgical infections susceptibility to augmentin will vary with geography and time. local susceptibility data should be consulted where available, and microbiological sampling and susceptibility testing performed where necessary. infections caused by amoxicillin susceptible organisms are amenable to augmentin treatment due to its amoxicillin content. mixed infections caused by amoxicillin susceptible organism in conjunction with augmentin susceptible beta-lactamase-producing organisms may therefore be treated by augmentin.

Noua Zeelandă - engleză - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - rosiglitazone maleate 1.33mg equivalent to 1 mg rosiglitazone - film coated tablet - 1 mg - active: rosiglitazone maleate 1.33mg equivalent to 1 mg rosiglitazone excipient: hypromellose lactose monohydrate magnesium stearate opadry yellow oy-l-22809 powdered cellulose sodium starch glycolate

Noua Zeelandă - engleză - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - rosiglitazone maleate 2.65mg equivalent to 2 mg rosiglitazone - film coated tablet - 2 mg - active: rosiglitazone maleate 2.65mg equivalent to 2 mg rosiglitazone excipient: hypromellose lactose monohydrate magnesium stearate opadry pink oy-l-24802 powdered cellulose sodium starch glycolate

Noua Zeelandă - engleză - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - rosiglitazone maleate 5.3mg equivalent to 4 mg rosiglitazone - film coated tablet - 4 mg - active: rosiglitazone maleate 5.3mg equivalent to 4 mg rosiglitazone excipient: hypromellose lactose monohydrate magnesium stearate opadry orange oy-l-23028 powdered cellulose sodium starch glycolate